Everolimus
"Everolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.
| Descriptor ID |
D000068338
|
| MeSH Number(s) |
D02.540.505.760.500
|
| Concept/Terms |
Everolimus- Everolimus
- SDZ RAD
- RAD, SDZ
- SDZ-RAD
- 40-O-(2-hydroxyethyl)-rapamycin
|
Below are MeSH descriptors whose meaning is more general than "Everolimus".
Below are MeSH descriptors whose meaning is more specific than "Everolimus".
This graph shows the total number of publications written about "Everolimus" by people in this website by year, and whether "Everolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Everolimus" by people in Profiles.
-
Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010 Feb; 24(2):447-63.